Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.

Antimicrobial agents and chemotherapy - 1 Mar 2012

Wang Chunfu, Huang Haichang, Valera Lourdes, Sun Jin-Hua, O'Boyle Donald R, Nower Peter T, Jia Lingling, Qiu Dike, Huang Xin, Altaf Aneela, Gao Min, Fridell Robert A

Abstract excerpt

BMS-790052, a first-in-class hepatitis C virus (HCV) replication complex inhibitor, targeting nonstructural protein 5A (NS5A), displays picomolar to nanomolar potency against genotypes 1 to 5. This exceptional potency translated into robust anti-HCV activity in clinical studies with HCV genotype 1-infected subjects. To date, all BMS-790052-associated resistance mutations have mapped to the N-terminal region of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Inhibitory Concentration 50
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polyethylene Glycols

Share to Pyrones

Share to Replicon

Share to RNA-Dependent RNA Polymerase

Share to Triazoles

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22214777
DOI: 10.1128/AAC.05977-11
PMCID: PMC3294925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.PMID 22214777Read ↗

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.Semantic proximity Read ↗

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.Semantic proximity Read ↗

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Semantic proximity Read ↗

Identification of hepatitis C virus NS5A inhibitors.Semantic proximity Read ↗

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Semantic proximity Read ↗

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.Semantic proximity Read ↗

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Semantic proximity Read ↗

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.